
Twelve years of multiples investors have paid for Bajaj Healthcare Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Bajaj Healthcare Ltd trades at a P/E of 43.83×.
Twelve years of audited numbers for Bajaj Healthcare Ltd, switchable between annual and quarterly views, consolidated or standalone.
Bajaj Healthcare Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current reported EPS of ₹6.72.
Disclosed business segments at Bajaj Healthcare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Bajaj Healthcare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Why someone would buy Bajaj Healthcare Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Bajaj Healthcare Ltd's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
Robust 49.30% quarterly profit growth indicates strong recent operational performance.
Healthy debt-to-equity ratio of 0.48 indicates manageable leverage and lower financial risk.
Substantial 59.2% promoter holding reflects strong confidence in long-term prospects.
Attractive P/E ratio of 28.30, lower than sector P/E 37.98.
Strong 10.07% EBITDA CAGR over five years reflects operational efficiency.
Significant decrease in promoter holding to 59.2% may signal reduced confidence.
Low Return on Equity (ROE) of 10.70% compared to industry peers.
ROCE of 11.40% is considerably lower than peers, indicating inefficient capital utilization.
Negative net profits in recent quarters indicate inconsistent profitability and operational challenges.
Poor stock performance with -22.75% YTD return raises investor concerns.
Trim if P/E re-rates above 57. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 47.23. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Bajaj Healthcare Ltd is highlighted for quick read-across.
| Company Name |
|---|
Aarey Drugs & Pharmaceuticals Ltd |
Aarti Drugs Ltd |
Aarti Pharmalabs Ltd |
Ajanta Pharma Ltd |
Akums Drugs & Pharmaceuticals Ltd |
Albert David Ltd |
Alivus Life Sciences Ltd |
Alkem Laboratories Ltd |
Alpa Laboratories Ltd |
Amrutanjan Health Care Ltd |
Alembic Pharmaceuticals Ltd |
Astrazeneca Pharma India Ltd |
Aurobindo Pharma Ltd |
Bafna Pharmaceuticals Ltd |
Bajaj Healthcare LtdCurrent Stock |
Bal Pharma Ltd |
Biocon Ltd |
Biofil Chemicals & Pharmaceuticals Ltd |
Bliss GVS Pharma Ltd |
Blue Jet Healthcare Ltd |
Brooks Laboratories Ltd |
Caplin Point Laboratories Ltd |
Cipla Ltd |
Cohance Lifesciences Ltd |
Concord Biotech Ltd |
Dishman Carbogen Amcis Ltd |
Divis Laboratories Ltd |
Dr Reddys Laboratories Ltd |
Emcure Pharmaceuticals Ltd |
ERIS Lifesciences Ltd |
FDC Ltd |
Gland Pharma Ltd |
Glaxosmithkline Pharmaceuticals Ltd |
Glenmark Pharmaceuticals Ltd |
Granules India Ltd |
Gufic BioSciences Ltd |
Haleos Labs Limited |
Hester Biosciences Ltd |
Hikal Ltd |
Indoco Remedies Ltd |
Ind-Swift Laboratories Ltd |
Innova Captab Ltd |
IOL Chemicals & Pharmaceuticals Ltd |
Ipca Laboratories Ltd |
Jagsonpal Pharmaceuticals Ltd |
J B Chemicals & Pharmaceuticals Ltd |
Jubilant Pharmova Ltd |
Kilitch Drugs (India) Ltd |
Kopran Ltd |
Krebs Biochemicals & Industries Ltd |
Lasa Supergenerics Ltd |
Laurus Labs Ltd |
Lincoln Pharmaceuticals Ltd |
Lupin Ltd |
Lyka Labs Ltd |
Mangalam Drugs and Organics Ltd |
Mankind Pharma Ltd |
Marksans Pharma Ltd |
Medicamen Biotech Ltd |
Medico Remedies Ltd |
Morepen Laboratories Ltd |
Natco Pharma Ltd |
Nectar Lifescience Ltd |
Neuland Laboratories Ltd |
NGL Fine Chem Ltd |
OneSource Specialty Pharma Ltd |
Orchid Pharma Ltd |
Ortin Global Ltd |
Panacea Biotec Ltd |
Pfizer Ltd |
Procter & Gamble Health Ltd |
Piramal Pharma Ltd |
RPG Life Sciences Ltd |
Sai Life Sciences Ltd |
Sanofi India Ltd |
Sanofi Consumer Healthcare India Ltd |
Senores Pharmaceuticals Ltd |
Shilpa Medicare Ltd |
Sigachi Industries Ltd |
SMS Pharmaceuticals Ltd |
Solara Active Pharma Sciences Ltd |
Sun Pharma Advanced Research Company Ltd |
Strides Pharma Science Ltd |
Sun Pharmaceutical Industries Ltd |
Supriya Lifescience Ltd |
Syncom Formulations (India) Ltd |
Themis Medicare Ltd |
Torrent Pharmaceuticals Ltd |
Unichem Laboratories Ltd |
Valiant Laboratories Ltd |
Venus Remedies Ltd |
Vineet Laboratories Ltd |
Viyash Scientific Ltd |
Wanbury Ltd |
Windlas Biotech Ltd |
Wockhardt Ltd |
Zim Laboratories Ltd |
Zydus Lifesciences Ltd |
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Bajaj Healthcare Ltd — derived from the live tape, not yesterday's close.
Bajaj Healthcare Ltd last traded at ₹293.5 with an intraday range of ₹292–₹298.4 — live indicator, pivot and CPR signals below.
Standard pivot — most widely referenced.
| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 310.07 | +16.57 | +5.64% |
| R3 | 303.67 | +10.17 | +3.46% |
| R2 | 301.03 | +7.53 | +2.57% |
| R1 | 297.27 | +3.77 | +1.28% |
| PIVOT | 294.63 | 1.13 | 0.39% |
| CURRENT | 293.50 | — | — |
| S1 | 278.07 | -15.43 | -5.26% |
| S2 | 284.47 | -9.03 | -3.08% |
| S3 | 288.23 | -5.27 | -1.79% |
| S4 | 290.87 | -2.63 | -0.90% |
BAJAJHCARE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: 296.05 ~ 298.4
Trading Inside opening range
Daily traded volume and delivery percentage for Bajaj Healthcare Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Bajaj Healthcare Ltd stood at 46.5% of traded volume, against a 20-day average of 41.8%.
Filings Bajaj Healthcare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Promoter, director and designated-employee transactions in Bajaj Healthcare as reported to SEBI — buying and selling signals from the people who know the business best.
Bajaj Healthcare insider activity below tracks 12 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| SAJANKUMAR RAMESHWARLAL BAJAJ | Insider | 18 Mar 2026 | buy | +4.55 L | ₹15.38 Cr | ₹338.00 |
| ANIL CHAMPALAL JAIN | Insider | 18 Mar 2026 | buy | +4.55 L | ₹15.38 Cr | ₹338.00 |
| SAJANKUMAR RAMESHWARLAL BAJAJ | Insider | 18 Mar 2026 | buy | +4.55 L | ₹15.38 Cr | ₹338.00 |
| ANIL CHAMPALAL JAIN | Insider | 18 Mar 2026 | buy | +4.55 L | ₹15.38 Cr | ₹338.00 |
| ANIL CHAMPALAL JAIN | Insider | 17 Mar 2026 | buy | +7.1 K | ₹19.91 L | ₹280.60 |
| ANIL CHAMPALAL JAIN | Insider | 17 Mar 2026 | buy | +7.1 K | ₹19.91 L | ₹280.60 |
| ANIL CHAMPALAL JAIN | Insider | 16 Mar 2026 | buy | +7.6 K | ₹21.29 L | ₹280.12 |
| ANIL CHAMPALAL JAIN | Insider | 16 Mar 2026 | buy | +7.6 K | ₹21.29 L | ₹280.12 |
| ANIL CHAMPALAL JAIN | Insider | 13 Mar 2026 | buy | +3.0 K | ₹8.75 L | ₹291.50 |
| ANIL CHAMPALAL JAIN | Insider | 13 Mar 2026 | buy | +3.0 K | ₹8.75 L | ₹291.50 |
Every dividend, stock split and bonus issue Bajaj Healthcare has declared, sequenced by announce and record date.
Bajaj Healthcare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
What Bajaj Healthcare Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Bajaj Healthcare Ltd operates in the Healthcare, listed as NSE: BAJAJHCARE, BSE: 539872.

Bajaj HealthCare Limited is an Indian pharmaceutical company established in 1993 and headquartered in Thane. Its core business revolves around the development, manufacturing, marketing, and sale of pharmaceutical products across India and internationally. Their offerings span a wide range, catering to the pharmaceutical, nutraceutical, and food industries.
A significant portion of their business involves the production and supply of active pharmaceutical ingredients (APIs). These APIs cover a broad spectrum of therapeutic categories, including treatments for diabetes, infections (antibiotic, antiviral, antifungal), cardiovascular issues, respiratory ailments (anti-asthmatic, bronchodilator), and many others. The extensive list of therapeutic areas indicates a diverse portfolio designed to meet varied market demands.
Beyond APIs, Bajaj HealthCare also manufactures and provides pharmaceutical intermediates. These are crucial chemical compounds used in the synthesis of APIs. The company's production of intermediates demonstrates vertical integration within the pharmaceutical supply chain, allowing for greater control over quality and potentially reducing costs.
Finally, Bajaj HealthCare produces finished dosage forms, offering a variety of formulations such as tablets, capsules, sachets, and vials. This provides a complete solution to customers, offering both the raw materials and the final products. The inclusion of nutraceuticals and food supplements further diversifies their product offerings and expands their market reach.
In summary, Bajaj HealthCare operates as a fully integrated pharmaceutical company, from the production of basic intermediates to the manufacturing and distribution of finished pharmaceutical and nutraceutical products. Their broad therapeutic coverage and diverse product portfolio position them within a competitive market.
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
The current share price of Bajaj Healthcare Ltd (BAJAJHCARE) is ₹293.5. Today, the stock has declined by ₹1.05 (0.36%), trading in a range of ₹292 to ₹298.4. The stock opened at ₹296.1 with a trading volume of 66,224 shares.
Bajaj Healthcare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹0 crores, P/E ratio of 43.83, ROE of 4.27%, and ROCE of 11.40%. The dividend yield stands at 0.33%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Bajaj Healthcare Ltd (BAJAJHCARE) is ₹552.6, while the 52-week low is ₹272.35. Currently trading at ₹293.5, the stock is 7.5% away from its 52-week low and 46.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Bajaj Healthcare Ltd stock at ₹293.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.83 and P/B ratio of N/A. Today's performance shows a loss of 0.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Bajaj Healthcare Ltd offers a dividend yield of 0.33%, which means for every ₹100 invested at the current price of ₹293.5, you can expect to receive approximately ₹0.33 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Bajaj Healthcare Ltd's key financial metrics include: P/E Ratio: 43.83, P/B Ratio: N/A, ROE: 4.27%, ROCE: 11.40%, Dividend Yield: 0.33%, EPS: ₹6.72, Book Value: ₹167.01, Debt-to-Equity: 46.73, and Current Ratio: N/A. The company's market cap stands at ₹0 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Bajaj Healthcare Ltd stock opened at ₹296.1 and is currently trading at ₹293.5, showing a decline of ₹1.05 (0.36%). The intraday high is ₹298.4 and low is ₹292. The trading volume stands at 66,224 shares, indicating moderate market participation today.
Bajaj Healthcare Ltd has a Price-to-Earnings (P/E) ratio of 43.83, which means investors are willing to pay ₹43.83 for every ₹1 of earnings. With an EPS of ₹6.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Bajaj Healthcare Ltd (BAJAJHCARE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Peers, sector trends, screeners and strategy playbooks contextual to this stock.